3B Blackbio Dx Limited stock analysis

TRUPCR® continues to strengthen its presence in international markets, with products reaching more than 70 countries and over 200 customers across Europe, the Middle East, Asia-Pacific, Latin America, Africa and North America. During FY 2025 26, our export business maintained its growth momentum, supported by increasing business from existing markets, expansion of our distribution network, new product registrations,

The rapid diagnostics business also progressed further, with Antimicrobial Resistance (AMR) becoming an important area of focus. 3B BLACKBIO DX LIMITED CIN: L24211MP1972PLC001131 27 Going forward, the Company will remain focused on new market expansion, deeper penetration in existing markets, regulatory approvals and development of new products. With a growing international customer base, broad diagnostic portfolio a

Strong domestic demand, continued investment and policy support helped sustain economic activity across sectors. This stable macroeconomic environment provided a favorable backdrop for businesses to pursue growth, expand capacity and invest in new opportunities. Demand for agrochemicals remains closely linked to cropping patterns, monsoon conditions, pest incidence and farmer economics.

Molecular diagnostic is a very small percentage of the entire diagnostic. That is the reason why we command higher margin profitability. But overall, if we say Indian market is say around between INR500 crores to INR600 crores, we are now almost, you can say, 15% approximately which is a very high footprint.

So if you see standalone last year versus this year, so there is a growth of around 7.1% on the standalone non-export revenue. And if we include the export growth of say 25 % odd, we reach a growth of consolidated growth of 10 %. So we started mainly with the Indian market way back in 2015.

Analyst/Investor Meets: The Managing Director has conference calls with institutional investors and analysts. Presentations made to institutional investors and analysts are uploaded on BSE through its respective portal. Details of Compliance with mandatory requirements: The Company has complied with all applicable mandatory requirements of Corporate Governance as specified in Regulations 17 to 27 read with Schedule V

Now we have a good grip of the NGS assays, however, commercialization is challenging as the field is highly competitive and labs try to make their own kits (homebrew) which is an old methodology and used in PCR as well. TRUNGS® is focussed on very niche products in this segment, hence, we do not expect major high growth / revenue from NGS immediately, however, it will be gradual. In FY 2024- tumors such as lung, gast